Tirzepatide immunogenicity on pharmacokinetics, efficacy, and safety: analysis of data from Phase 3 studies.

Garrett MullinsMichael E HodsdonYing Grace LiGreg AnglinShweta UrvaKaren SchneckJennifer N BardosRicardo Fonseca MartinsKatelyn BrownBoris Calderón

Published in: The Journal of clinical endocrinology and metabolism (2023)

Immunogenicity did not impact tirzepatide pharmacokinetics or efficacy. Majority hypersensitivity or injection site reactions experienced by TE ADA+ patients were mild to moderate in severity.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
electronic health record
big data
machine learning
drug induced
deep learning